Corgentech announces patent issuance for E2F transcription factor decoy technology.Corgentech, Inc. (South San Francisco South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , CA) a biotechnology company, announced that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has issued United States Patent 6,774,118. The patent covers a method for preventing formation of neointimal thickening leading to restenosis and vessel occlusion with any double-stranded oligonucleotide decoy DECOY. A pond used for the breeding and maintenance of water-fowl. 11 Mod. 74, 130; S. C. 3 Salk. 9; Holt, 14 11 East, 571. that binds to the transcription factor, E2F E2F E-Mail to Fax , regardless of the sequence of such decoy. The patent is assigned to Brigham and Women's Hospital Brigham and Women's Hospital (BWH) is a hospital in the Longwood Area of the Boston, Massachusetts neighborhood of Mission Hill. With Massachusetts General Hospital, it is one of the two founding members of Partners HealthCare. (Boston, MA), and is exclusively licensed to Corgentech. E2F is a transcription factor family that is responsible for the activation of genes involved in the growth and proliferation of the smooth muscle cells that can lead to neointimal hyperplasia, plaque build-up, venous graft failure graft failure Clinical immunology Loss of function in a transplanted organ or tissue. See Graft. or restenosis. "We are very pleased by the issuance of the latest, and one of the most fundamental, United States patents protecting our E2F Decoy technology," said John P. McLaughlin, Corgentech's president and chief executive officer. "United States Patent 6,774,118 further solidifies our intellectual property position as we move toward commercial development of our lead product candidate." In October 2003, Corgentech, Inc. and Bristol-Myers Squibb Company entered into an agreement to jointly develop and commercialize Corgentech's edifoligide (E2F Decoy), a first-of-its-kind treatment currently in Phase III development for the prevention of vein graft failure following coronary artery bypass graft coronary artery bypass graft n. Abbr. CABG A surgical procedure in which a section of vein or other conduit is grafted between the aorta and a coronary artery below the region of an obstruction in that artery. and peripheral artery (i.e., leg) bypass graft surgery. Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, such as arthritis and dermatitis, and cancer. Corgentech, Inc. +1-650-624-9600 www.corgentech.com |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion